Yahoo
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:0
Yahoo
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a
Yahoo
H.C. Wainwright upgraded Rapt Therapeutics (RAPT) to Buy from Neutral with a $10 price target after Rapt and a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China, announced that they have entered into an exclusive license agreement for JYB1904, or RPT904, a clinical-stage, half-life extended anti-immunoglobulin E monoclonal antibody. Rapt plans to pursue development of RPT904 initially in food allergy, which is a market that represents “a large and lucrative niche,”
Yahoo
Progressive, EverQuote upgraded: Wall Street's top analyst calls
Yahoo
Under the licence terms, Jemincare is set to obtain an upfront payment of $35m.
Yahoo
RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares are trading higher after the company disclosed a partnership with Shanghai Jemincare Pharmaceutical. The collaboration is for an exclusive license agreement to develop and commercialize RPT904, a novel anti-IgE monoclonal antibody worldwide, excluding mainland China, Hong Kong, Macau, and Taiwan. RPT904 is designed to provide a potential alternative to omalizumab (Xolair), addressing allergic conditions such as asthma and chronic spontaneous urticaria
Current Value
$1.191 Year Return
Current Value
$1.191 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TT | <0.01% | $90.07B | +58.77% | 0.83% |
SWI | 0.01% | $2.50B | +31.20% | 0.00% |
DT | -0.02% | $16.35B | -5.86% | 0.00% |
CWT | -0.02% | $2.58B | -5.39% | 2.58% |
ALL | 0.02% | $48.90B | +16.09% | 1.99% |
CRM | 0.03% | $320.27B | +19.94% | 0.48% |
LNT | 0.03% | $15.06B | +20.39% | 3.27% |
UHAL.B | 0.03% | $12.77B | -0.14% | 0.31% |
CCEC | 0.04% | $1.00B | +2.08% | 3.22% |
EBAY | -0.04% | $31.02B | +53.58% | 1.65% |
JBSS | 0.05% | $1.03B | -14.16% | 0.96% |
AFL | 0.06% | $58.04B | +23.07% | 1.92% |
PNNT | -0.07% | - | - | 13.16% |
HAIN | -0.07% | $453.68M | -54.23% | 0.00% |
CPNG | 0.07% | $39.57B | +51.52% | 0.00% |
GEL | 0.08% | $1.28B | -10.72% | 5.84% |
EVH | 0.09% | $1.19B | -65.95% | 0.00% |
JWN | -0.10% | $3.99B | +23.97% | 3.14% |
XRAY | -0.10% | $3.86B | -44.54% | 3.32% |
ETON | 0.11% | $432.55M | +265.77% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PLYA | 59.11% | $1.50B | +49.64% | 0.00% |
RUM | 50.95% | $5.83B | +139.70% | 0.00% |
DESP | 38.49% | $1.61B | +97.34% | 0.00% |
HMC | 34.99% | $44.64B | -11.35% | 4.97% |
AVXL | 34.80% | $865.12M | +53.61% | 0.00% |
GCMG | 33.38% | $604.34M | +53.65% | 3.28% |
ICHR | 28.02% | $992.43M | -22.21% | 0.00% |
UCTT | 26.89% | $1.68B | -3.32% | 0.00% |
ACHV | 26.11% | $103.17M | -41.63% | 0.00% |
ABBV | 25.97% | $301.60B | +3.35% | 3.71% |
WLK | 25.91% | $15.22B | -14.54% | 1.73% |
THRM | 25.75% | $1.23B | -18.17% | 0.00% |
COHU | 24.68% | $1.14B | -28.58% | 0.00% |
RIO | 24.36% | $77.11B | -12.18% | 6.97% |
RXRX | 24.33% | $2.94B | -26.39% | 0.00% |
MPWR | 23.89% | $34.09B | +13.50% | 0.72% |
XNCR | 23.63% | $1.43B | +3.18% | 0.00% |
TRTX | 23.49% | $671.70M | +28.28% | 11.51% |
ALGM | 23.41% | $4.59B | -9.51% | 0.00% |
SWTX | 23.40% | $2.69B | -14.44% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MFIN | -22.91% | - | - | 4.60% |
SPTN | -22.16% | $602.19M | -21.72% | 4.90% |
PANW | -14.61% | $122.92B | +10.13% | 0.00% |
REYN | -13.78% | $5.81B | +1.73% | 3.33% |
CALM | -13.69% | $5.42B | +96.44% | 2.65% |
AGS | -13.63% | $486.62M | +40.54% | 0.00% |
WK | -12.61% | $5.94B | +2.54% | 0.00% |
HNST | -12.44% | $617.88M | +111.76% | 0.00% |
WMT | -12.15% | $753.61B | +72.83% | 0.89% |
WES | -12.07% | $16.15B | +45.11% | 7.47% |
CBOE | -11.97% | $21.11B | +6.85% | 1.18% |
AWI | -11.49% | $6.56B | +53.22% | 0.76% |
WOW | -11.44% | $370.47M | +18.11% | 0.00% |
IEP | -11.19% | $4.96B | -45.03% | 35.48% |
LUNR | -10.94% | $2.00B | +762.65% | 0.00% |
LBTYA | -10.81% | $4.25B | +7.55% | 0.00% |
MUSA | -10.46% | $9.76B | +32.84% | 0.37% |
CIG | -10.41% | $3.41B | +4.03% | 0.00% |
CENT | -9.97% | $2.41B | -1.60% | 0.00% |
LBTYK | -9.92% | $4.34B | +1.97% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBTO | -<0.01% | $272.00M | 0.07% |
XMPT | -0.07% | $199.91M | 1.98% |
IBHF | -0.09% | $689.95M | 0.35% |
BSV | 0.11% | $33.33B | 0.04% |
IBTI | -0.12% | $888.84M | 0.07% |
BTF | -0.13% | $37.18M | 1.24% |
KXI | -0.15% | $681.02M | 0.41% |
IBTF | 0.16% | $2.23B | 0.07% |
IBDR | -0.16% | $3.16B | 0.1% |
IBTL | -0.19% | $273.00M | 0.07% |
IBTM | -0.27% | $258.71M | 0.07% |
FLDR | -0.30% | $682.72M | 0.15% |
IEI | -0.35% | $15.35B | 0.15% |
AGGY | 0.35% | $923.62M | 0.12% |
HYZD | -0.36% | $176.04M | 0.43% |
SEIX | 0.37% | $307.45M | 0.57% |
SHY | 0.39% | $23.17B | 0.15% |
IBTJ | -0.39% | $481.88M | 0.07% |
UTWO | -0.40% | $389.72M | 0.15% |
BOND | 0.40% | $5.14B | 0.7% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 32.10% | $275.22M | 0% |
QQA | 31.21% | $148.52M | 0% |
IBB | 25.67% | $6.39B | 0.45% |
XBI | 25.25% | $6.27B | 0.35% |
EFAA | 24.24% | $105.12M | 0% |
FHLC | 23.73% | $2.70B | 0.084% |
VHT | 23.43% | $16.72B | 0.1% |
FTHI | 23.43% | $1.14B | 0.75% |
PBE | 22.75% | $254.98M | 0.58% |
XPH | 22.45% | $167.55M | 0.35% |
IHE | 22.35% | $607.76M | 0.39% |
BBH | 22.21% | $399.71M | 0.35% |
XLV | 22.06% | $38.02B | 0.09% |
XSD | 21.86% | $1.48B | 0.35% |
BBAX | 21.84% | $4.60B | 0.19% |
FBT | 21.76% | $1.20B | 0.56% |
IYH | 21.74% | $3.15B | 0.39% |
EPP | 21.64% | $1.86B | 0.48% |
GNOM | 21.47% | $69.64M | 0.5% |
DRIV | 21.29% | $391.96M | 0.68% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -16.37% | $195.31M | 0.85% |
TAIL | -12.97% | $64.78M | 0.59% |
TPMN | -11.71% | $34.23M | 0.65% |
VNLA | -8.08% | $2.31B | 0.23% |
ICSH | -7.78% | $5.25B | 0.08% |
BOXX | -7.64% | $4.86B | 0.1949% |
MEAR | -5.51% | $771.37M | 0.25% |
JUCY | -5.33% | $302.22M | 0.6% |
UNG | -4.76% | $664.75M | 1.06% |
BSJP | -4.67% | $1.00B | 0.42% |
DBA | -4.57% | $828.49M | 0.93% |
CCOR | -3.84% | $81.54M | 1.18% |
UUP | -3.82% | $634.18M | 0.77% |
WEAT | -3.43% | $123.99M | 0.28% |
XONE | -3.42% | $535.90M | 0.03% |
SGOV | -3.22% | $31.97B | 0.09% |
EWZS | -3.22% | $109.69M | 0.6% |
BSSX | -3.09% | $63.89M | 0.18% |
GSY | -2.97% | $2.48B | 0.23% |
TBIL | -2.88% | $4.85B | 0.15% |